贝伐珠单抗对比抗EGFR单抗治疗转移性结直肠癌患者疗效及不良反应  

Comparison of Anti EGFR Monoclonal Antibody Bevacizumab Treatment Efficacy and Adverse Reactions of Patients With Metastatic Colorectal Cancer

作　　者：张华[1] 陆文斌[1] 邓建忠[1] 金建华[1] 

机构地区：[1]江苏大学附属武进人民医院肿瘤内科,江苏常州210000

出　　处：《中国继续医学教育》2016年第27期158-159,共2页China Continuing Medical Education

摘　　要：目的探讨贝伐珠单抗对比抗EGFR单抗治疗转移性结直肠癌的疗效。方法收集我院转移性结直肠癌患者,分为研究组(接受抗EGFR单抗治疗)和对照组(接受贝伐珠单抗治疗)。对比两组治疗3个周期时治疗疗效及中位总生存时间、不良反应。结果两组治疗疗效及中位总生存时间比较,差异无统计学意义(P>0.05)。研究组和对照组骨髓抑制、皮疹、消化道反应发生情况比较,差异有统计学意义(P<0.05)。结论抗EGFR单抗与贝伐珠单抗治疗转移性结直肠癌疗效相近,但前者不良反应发生率更少。Objective To investigate the efficacy of bevacizumab in comparison of anti EGFR monoclonal antibody in the treatment of metastatic colorectal cancer. Methods In our hospital from metastatic colorectal cancer patients, divided into study group（treated with anti EGFR monoclonal antibody therapy） and control group（bevacizumab treatment）. Compare the curative effect of the two groups and the median overall survival time and adverse reaction of the 3 groups. Results There was no significant difference between the two groups in the therapeutic effect and the median overall survival time（P〉0.05）. In the study group and control group, the difference was statistically significant（P〈0.05）, the incidence of bone marrow suppression, skin rash and digestive tract reaction were compared. Conclusion Anti EGFR monoclonal antibody and bevacizumab for metastatic colorectal cancer is similar, but the former less incidence of adverse reactions.

关 键 词：转移 直肠癌 疗效 

分 类 号：R735.37[医药卫生—肿瘤]